Crime, Drugs & Public Order
Tranq (Xylazine)
The supply got worse than the law imagined. An animal tranquilizer naloxone can't reverse, cut into the street supply.
The Stakes
Just as families learned the word 'fentanyl,' the supply changed underneath them. Xylazine — 'tranq' — is a veterinary sedative, never meant for humans, now cut into the fentanyl supply. It deepens sedation, causes wounds that can lead to amputation, and, because it isn't an opioid, naloxone doesn't reverse the xylazine part. A bystander can do everything right with a Narcan spray and still watch someone not wake up. The street supply mutated faster than our laws, our test strips, and our treatment protocols — and people are paying for the lag.
The Receipts
Every figure cites a primary federal source. Tap a chip to check it yourself.
DEA alert, 2023The DEA issued a national Public Safety Alert in March 2023 warning of the widespread threat of fentanyl mixed with xylazine — its first such alert naming the combination as a distinct danger.
DEA ↗~23% of powderIn 2022 DEA lab testing, roughly 23% of seized fentanyl powder and about 7% of fentanyl pills contained xylazine — meaning a large share of the powder supply was already contaminated.
DEA ↗48 of 50 statesDEA reported seizing fentanyl-xylazine mixtures in 48 of 50 states — this is a national contamination of the supply, not a regional problem.
DEA ↗Naloxone won't reverse itBecause xylazine is not an opioid, naloxone does not reverse its sedative effects — though responders should still give naloxone, since fentanyl is almost always present alongside it.
CDC ↗Rising in OD deathsCDC analysis found xylazine detected in a sharply rising share of illicitly-manufactured-fentanyl overdose deaths through 2022, tracking the contamination of the supply.
CDC MMWR ↗Their Best Argument — and Why It Fails
The steelman
Scheduling xylazine as a controlled substance risks cutting off a legitimate veterinary drug and could push the illicit market toward something even worse, as past crackdowns did. The real answer is wound-care services, drug-checking, and treatment — not another front in the drug war.
The rebuttal
The veterinary-access concern is legitimate, and any control scheme should carve out lawful animal use — that's a solvable design problem, not a reason to do nothing. But xylazine entered the supply because it was an unregulated, cheap cutting agent, and naloxone can't reverse it: a responder can do everything right and still lose someone. Drug-checking and wound care matter and should expand, yet they manage a poisoned supply rather than pressure it. The supply changed faster than the law; the law has to catch up — scheduling the illicit trafficking of xylazine while protecting veterinarians, expanding test strips that detect it, and updating overdose protocols. Harm reduction and supply control point the same direction here.
The Conservative Fix
- 1
Schedule illicit xylazine trafficking under federal law with an explicit carve-out for legitimate veterinary use.
Federal - 2
Fund and distribute xylazine test strips so users and responders know what's in the supply.
State / Local - 3
Train first responders that naloxone is still warranted but won't reverse xylazine, and fund wound-care outreach.
State / Local - 4
Sanction the precursor and supply chains importing illicit xylazine, as with fentanyl precursors.
Federal
Answer the Muster
Who decides this: Your U.S. House member and Senators (scheduling and precursor controls are federal; test strips and outreach are state/local)
I'm a constituent in [district]. Xylazine — tranq — is in the fentanyl supply in 48 states, and naloxone can't reverse it. I'm asking [official] to schedule illicit xylazine trafficking while protecting veterinary use, and to fund test strips. Where does [he/she] stand?